RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU

Their core work

RIVM is the Netherlands' national public health and environmental research institute, serving as the Dutch government's primary scientific advisory body on health risks, environmental safety, and disease prevention. In H2020, they bring deep expertise in chemical risk assessment, nanosafety regulation, infectious disease surveillance, and human biomonitoring — acting as the bridge between scientific evidence and regulatory policy. Their work directly shapes how Europe regulates nanomaterials, monitors population-level chemical exposure, and tracks vaccine effectiveness across member states.

What they specialise in

How they've shifted over time

In the early H2020 period (2014–2018), RIVM focused heavily on nanosafety regulation and environmental risk — projects like NanoREG II, caLIBRAte, ProSafe, and INSPIRATION dominated, alongside foundational infectious disease work in metagenomics and virus discovery (VIROGENESIS). By the later period (2018–2022), the emphasis shifted toward population-level health monitoring: human biomonitoring (HBM4EU), exposome research, organ-on-a-chip technologies, and large-scale biobanking, with risk communication becoming a recurring theme. The trajectory shows a move from characterizing individual hazards (nanomaterials, specific pathogens) toward integrated exposure science and regulatory tools that assess cumulative health impacts.

RIVM is moving toward integrated human exposure science — combining biomonitoring, exposome analysis, and advanced in-vitro models to replace traditional single-substance risk assessment with cumulative, population-level approaches.

How they like to work

RIVM overwhelmingly operates as a participant (55 of 62 projects), bringing specialist regulatory and risk assessment expertise to large consortia rather than leading them. With 962 unique partners across 51 countries, they function as a high-connectivity hub — one of the most networked public health institutes in Europe. Their few coordinator roles (4 projects, including EuroMix) tend to be in areas where regulatory science is the central question, suggesting they lead when the project specifically requires a national regulatory body's authority.

RIVM has collaborated with 962 unique partners across 51 countries, making it one of the most broadly connected research institutes in H2020. Their network spans nearly all EU member states plus associated countries, with particularly strong ties to public health agencies, regulatory bodies, and universities across Western and Northern Europe.

What sets them apart

RIVM sits at the intersection of scientific research and government regulation in a way few other H2020 participants can match — they are simultaneously a research institute producing primary data and the national authority that shapes Dutch and EU policy based on that data. This dual identity makes them uniquely valuable in projects where the end goal is regulatory guidance, standard-setting, or policy implementation, not just publications. For consortium builders, partnering with RIVM means direct access to regulatory thinking and a credible pathway from research results to real-world policy impact.

Highlights from their portfolio

• HBM4EU
  Largest single project (EUR 4.2M to RIVM) — the European Human Biomonitoring Initiative, a flagship effort to understand population-level chemical exposure across Europe.
• EuroMix
  One of RIVM's rare coordinator roles (EUR 1M), focused on assessing combined dietary exposure to chemical mixtures — a regulatory frontier.
• PERISCOPE
  Second-largest funding (EUR 1.9M), a major IMI-linked project on pertussis vaccine correlates of protection, reflecting RIVM's vaccine expertise at scale.